Fig. 2: Metastatic melanoma cells show high sensitivity to next-generation synthetic ecteinascidins. | Nature Communications

Fig. 2: Metastatic melanoma cells show high sensitivity to next-generation synthetic ecteinascidins.

From: Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity

Fig. 2

a, b Chemical structure of ecubectedin a and PM54 b, two next-generation synthetic ecteinascidins analogs of lurbinectedin. The modifications are highlighted in red. The moiety of the molecule interacting with DNA is indicated. Molecular Weight (MW) is indicated. c, d Indicated melanoma cells were treated with increasing concentrations of ecubectedin c or PM54 d, for 72 h. Mean growth is shown relative to vehicle (DMSO)-treated cells. Error bars indicate mean values ± Standard Deviation (SD) for three biological triplicates. Differentiated (MITF-High, proliferative) melanoma cells are shown in blue, while undifferentiated (MITF-low, invasive) melanoma cells are shown in red. Hyperpigmented melanoma cells with acquired resistance to vemurafenib are shown in green. Immortalized Hermes3A melanocytes, skin keratinocyte HaCaT and embryonic fibroblastic MRC5 cells are shown in violet. Source data are provided as a Source Data file.

Back to article page